Abstract
Objective To fine map the association between human leukocyte antigen (HLA) genes and Parkinson’s disease (PD) that was discovered using genome-wide association studies (GWASs).
Methods We performed a thorough analysis of the HLA locus in 13,770 PD patients, 20,214 proxy-cases and 490,861 controls of European origin. We used GWAS data to impute HLA types and performed multiple regression models to examine the association of specific HLA types, different haplotypes and specific amino acid changes. We further performed conditional analyzes to identify specific alleles or genetic variants that drive the association with PD.
Results Four HLA types were associated with PD after correction for multiple comparisons, HLA-DQA1*03:01, HLA-DQB1*03:02, HLA-DRB1*04:01 and HLA-DRB1*04:04. Haplotype analyzes followed by amino-acid analysis and conditional analyzes suggested that the association is protective and primarily driven by three specific amino acid polymorphisms present in most HLA-DRB1*04 subtypes - 11V, 13H and 33H (OR=0.87 95%CI=0.83-0.90, p<8.23×10−9 for all three variants). No other effects were present after adjustment for these amino acids.
Conclusions Our results suggest that specific variants in the HLA-DRB1 gene are associated with reduced risk of PD, providing additional evidence for the role of the immune system in PD. Although effect size is small and has no diagnostic significance, understanding the mechanism underlying this association may lead to identification of new targets for therapeutics development.
Competing Interest Statement
Eric Yu - Reports no disclosures Aditya Ambati - Reports no disclosures Maren Stolp Andersen - Reports no disclosures Lynne Krohn - Reports no disclosures Mehrdad A. Estiar - Reports no disclosures Prabhjyot Saini - Reports no disclosures Konstantin Senkevich - Reports no disclosures Yuri L. Sosero - Reports no disclosures Ashwin Ashok Kumar Sreelatha - Reports no disclosures Jennifer A. Ruskey - Reports no disclosures Farnaz Asayesh - Reports no disclosures Dan Spiegelman - Reports no disclosures Mathias Toft - Received grants from Norwegian Parkinson Research Fund, grants from Reberg's legacy Marte K. Viken - Reports no disclosures Manu Sharma - Reports no disclosures Cornelis Blauwendraat - Reports no disclosures Lasse Pihlstrøm - Received grants from National Health Association, Norway, grants from South-Eastern Regional Health Authority, Norway Emmanuel Mignot - Reports non-financial support from Idorsia Pharmaceuticals Ltd, personal fees from Jazz Pharmaceutical, Alairion, ALPCO, INEXIA, Merck, Orexia, Rhythm and Sunovion Ziv Gan-Or - Reports personal fees from Idorsia, personal fees from Neuron23, personal fees from Handl Therapeutics, personal fees from Lysosomal Therapeutics Inc., personal fees from Deerfield, Lighthouse, Prevail Therapeutics, Ono Therapeutics, Denali and Inception Science
Funding Statement
This work was financially supported by grants from the Michael J. Fox Foundation, the Canadian Consortium on Neurodegeneration in Aging (CCNA), the Canada First Research Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for Healthy Lives initiative (HBHL), and Parkinson Canada. We would like to thank all members of the International Parkinson Disease Genomics Consortium (IPDGC). For a complete overview of members, acknowledgements and funding, please see http://pdgenetics.org/partners. This research was also supported in part by the Intramural Research Program of the NIH, National institute on Aging. HLA sequencing of samples from the Oslo Parkinson's disease study was supported by the Norwegian Parkinson Research Fund. PPMI - a public-private partnership - is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including Abbvie, Allergan, Amathus Therapeutics, Avid Radiopharmaceuticals, Biogen, BioLegend, Bristol-Myers Squibb, Celgene, Denali Therapeutics, GE Healthcare, Genentech, GlaxoSmithKline, Golub Capital, Handl Therapeutics, Insitro, Janssen, Lilly, Lundbeck, Merck, Meso Scale Discovery, Neurocrine Biosciences, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanofi Genzyme, Servier, Takeda, Teva, UCB, Verily and Voyager Therapeutics. This research has been conducted using the UK Biobank Resource under Application Number 35605. LP is supported by a grant from the National Health Association, Norway. MSA is supported by a grant from the South-Eastern Regional Health Authority, Norway. KS is supported by a postdoctoral fellowship from the Canada First Research Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for Healthy Lives initiative (HBHL). ZGO is supported by the Fonds de recherche du Québec - Santé (FRQS) Chercheurs-boursiers award.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Study protocols were approved by the MUHC REB (IRB00010120) and all participants signed informed consent before entering the study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Study funding: This work was financially supported by grants from the Michael J. Fox Foundation, the Canadian Consortium on Neurodegeneration in Aging (CCNA), the Canada First Research Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for Healthy Lives initiative (HBHL), and Parkinson Canada. We would like to thank all members of the International Parkinson Disease Genomics Consortium (IPDGC). For a complete overview of members, acknowledgements and funding, please see http://pdgenetics.org/partners. This research was also supported in part by the Intramural Research Program of the NIH, National institute on Aging. HLA sequencing of samples from the Oslo Parkinson’s disease study was supported by the Norwegian Parkinson Research Fund. PPMI – a public-private partnership – is funded by the Michael J. Fox Foundation for Parkinson’s Research and funding partners, including Abbvie, Allergan, Amathus Therapeutics, Avid Radiopharmaceuticals, Biogen, BioLegend, Bristol-Myers Squibb, Celgene, Denali Therapeutics, GE Healthcare, Genentech, GlaxoSmithKline, Golub Capital, Handl Therapeutics, Insitro, Janssen, Lilly, Lundbeck, Merck, Meso Scale Discovery, Neurocrine Biosciences, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanofi Genzyme, Servier, Takeda, Teva, UCB, Verily and Voyager Therapeutics. This research has been conducted using the UK Biobank Resource under Application Number 35605. LP is supported by a grant from the National Health Association, Norway. MSA is supported by a grant from the South-Eastern Regional Health Authority, Norway. KS is supported by a postdoctoral fellowship from the Canada First Research Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for Healthy Lives initiative (HBHL). ZGO is supported by the Fonds de recherche du Québec - Santé (FRQS) Chercheurs-boursiers award.
Disclosures: Eric Yu – Reports no disclosures
Aditya Ambati – Reports no disclosures
Maren Stolp Andersen – Reports no disclosures
Lynne Krohn – Reports no disclosures
Mehrdad A. Estiar – Reports no disclosures
Prabhjyot Saini – Reports no disclosures
Konstantin Senkevich – Reports no disclosures
Yuri L. Sosero – Reports no disclosures
Ashwin Ashok Kumar Sreelatha – Reports no disclosures
Jennifer A. Ruskey – Reports no disclosures
Farnaz Asayesh – Reports no disclosures
Dan Spiegelman – Reports no disclosures
Mathias Toft – Received grants from Norwegian Parkinson Research Fund, grants from Reberg’s legacy
Marte K. Viken – Reports no disclosures
Manu Sharma – Reports no disclosures
Cornelis Blauwendraat – Reports no disclosures
Lasse Pihlstrøm – Received grants from National Health Association, Norway, grants from South-Eastern Regional Health Authority, Norway
Emmanuel Mignot – Reports non-financial support from Idorsia Pharmaceuticals Ltd, personal fees from Jazz Pharmaceutical, Alairion, ALPCO, INEXIA, Merck, Orexia, Rhythm and Sunovion
Ziv Gan-Or – Reports personal fees from Idorsia, personal fees from Neuron23, personal fees from Handl Therapeutics, personal fees from Lysosomal Therapeutics Inc., personal fees from Deerfield, Lighthouse, Prevail Therapeutics, Ono Therapeutics, Denali and Inception Science
Data Availability
Code used for the analysis can be found at https://github.com/gan-orlab/. Summary statistics are included in the supplementary files. All other data is available upon request.
Glossary
- eQTL
- expression quantitative trait locus
- GWAS
- genome-wide association study
- GWAX
- genome-wide association study by proxy
- HLA
- human leukocyte antigen
- LD
- linkage disequilibrium
- MHC
- major histocompatibility complex
- PD
- Parkinson’s disease
- PRS
- polygenic risk score
- QC
- quality control
- SNP
- single nucleotide polymorphism
